UniQure's Stock Is Trading Higher As FDA Lifts Clinical Hold On Its Hemophilia B Gene Therapy Program

This post was originally published on this site

[unable to retrieve full-text content]The FDA has removed the clinical hold on uniQure NV’s (NASDAQ: QURE) hemophilia B gene therapy program after determining the company had satisfactorily addressed all identified is …

Related Posts